GlassScriptPhysician profile
Jaceson Banham
NPI 1295544344
$608.37
in general payments reported to CMS, 2019-2025
15 companies · $608 in 2025
The $608 reported for 2025 was more than what 75% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $608.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $608.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $608.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $85.62 | 2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $75.95 | 2025 | |
| Vanda Pharmaceuticals INC. | $73.54 | 2025 | Fanapt |
| Glaxosmithkline, LLC. | $55.63 | 2025 | Trelegy Ellipta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $45.52 | 2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.39 | 2025 | Jardiance |
| Viatris Specialty LLC | $35.94 | 2025 | Yupelri |
| Phathom Pharmaceuticals, INC. | $32.24 | 2025 | Voquezna |
| Pfizer INC. | $31.63 | 2025 | |
| Lilly USA, LLC | $28.60 | 2025 | Mounjaro, Zepbound |
| Otsuka America Pharmaceutical, INC. | $22.72 | 2025 | Rexulti |
| Xeris Pharmaceuticals, INC. | $21.97 | 2025 | Keveyis |
| Tactile Systems Technology INC | $21.07 | 2025 | Flexitouch Plus, Nimbl |
| Dexcom, INC. | $20.41 | 2025 | Dexcom G6 Transmitter |
| Edwards Lifesciences Corporation | $19.14 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaceson Banham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.